Michael Gelband’s Abivax ABVX Stock Holding History

Michael Gelband’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.3M	Buy	+227,200	New	+$25.7M	0.2%	75

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Michael Gelband's ABVX Position: Q2 2026 in Review

Michael Gelband reduced its Abivax (ABVX) stake by 78% in Q2 2026, selling an estimated $12.3M and leaving 31,209 shares worth $4.16M. The position accounts for 0.03% of the portfolio, ranked #557.

Michael Gelband first reported a position in ABVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $29M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Michael Gelband held 31,209 shares of Abivax worth $4.16M as of Q2 2026.
Michael Gelband sold 109,053 Abivax shares in Q2 2026, an estimated $12.3M.
Abivax made up 0.03% of Michael Gelband's portfolio in Q2 2026, its #557 holding.
Michael Gelband first reported a position in Abivax in Q4 2025 and has held it in 3 quarters since.
Michael Gelband's Abivax position peaked at $29M in Q4 2025.
302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.